ANI PHARMACEUTICALS, INC Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect
ANI PHARMACEUTICALS, INC (ANIP) reported Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect of $14.52 million for the 3-month period ending 2023-03-31, per its 10-Q filed 2023-05-08.
Discontinued › Cash Flow › Change in Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect · last filed 2023-05-08
- ANI PHARMACEUTICALS, INC cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2023-03-31 was $14.52M.
- ANI PHARMACEUTICALS, INC cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2022-03-31 was -$23.39M, a 235.94% decline year-over-year.
- ANI PHARMACEUTICALS, INC cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2021-03-31 was $17.21M.
- ANI PHARMACEUTICALS, INC cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2020-03-31 was -$41.95M.
- ANI PHARMACEUTICALS, INC cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2022 was -$52.07M, a 156.33% decline from fiscal 2021.
- ANI PHARMACEUTICALS, INC cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2021 was $92.43M.
- ANI PHARMACEUTICALS, INC cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2020 was -$54.49M, a 381.88% decline from fiscal 2019.
- ANI PHARMACEUTICALS, INC cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2019 was $19.33M, a 62.74% increase from fiscal 2018.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2023-03-31 | $14.52M 10-Q · filed 2023-05-08 | |||
| 2022-12-31 | -$52.07M 10-K · filed 2023-03-09 | |||
| 2022-09-30 | -$44.02M 10-Q · filed 2022-11-09 | |||
| 2022-06-30 | -$36.91M 10-Q · filed 2022-08-08 | |||
| 2022-03-31 | -$23.39M 10-Q · filed 2023-05-08 | |||
| 2021-12-31 | $92.43M 10-K · filed 2023-03-09 | |||
| 2021-09-30 | $7.39M 10-Q · filed 2022-11-09 | |||
| 2021-06-30 | $16.39M 10-Q · filed 2022-08-08 | |||
| 2021-03-31 | $17.21M 10-Q · filed 2022-05-10 | |||
| 2020-12-31 | -$54.49M 10-K · filed 2023-03-09 | |||
| 2020-09-30 | -$44.46M 10-Q · filed 2021-11-01 | |||
| 2020-06-30 | -$34.66M 10-Q · filed 2021-08-06 | |||
| 2020-03-31 | -$41.95M 10-Q · filed 2021-05-07 | |||
| 2019-12-31 | $19.33M 10-K · filed 2022-03-15 | |||
| 2019-09-30 | $16.67M 10-Q · filed 2020-11-05 | |||
| 2019-06-30 | -$2.42M 10-Q · filed 2020-08-06 | |||
| 2019-03-31 | -$4.79M 10-Q · filed 2020-05-07 | |||
| 2018-12-31 | $11.88M 10-K · filed 2021-03-11 | |||
| 2018-09-30 | $13.00M 10-Q · filed 2019-11-06 | |||
| 2018-06-30 | $23.85M 10-Q · filed 2019-08-07 | |||
| 2018-03-31 | $20.82M 10-Q · filed 2019-05-09 | |||
| 2017-12-31 | $3.78M 10-K · filed 2020-02-27 | |||
| 2017-09-30 | -$9.33M 10-Q · filed 2018-11-06 | |||
| 2017-06-30 | -$19.00M 10-Q · filed 2018-08-07 | |||
| 2017-03-31 | -$16.54M 10-Q · filed 2018-05-08 | |||
| 2016-12-31 | -$122.32M 10-K · filed 2019-02-27 | |||
| 2016-09-30 | -$133.53M 10-Q · filed 2017-11-02 | |||
| 2015-12-31 | -$14.35M 10-K · filed 2018-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |